0HNC Stock Overview
A biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 0HNC from our risk checks.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
BioMarin Pharmaceutical Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$71.60 |
| 52 Week High | US$94.51 |
| 52 Week Low | US$60.75 |
| Beta | 0.33 |
| 1 Month Change | 12.01% |
| 3 Month Change | 8.71% |
| 1 Year Change | -16.31% |
| 3 Year Change | -6.26% |
| 5 Year Change | -19.71% |
| Change since IPO | -21.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0HNC | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 1.7% | -1.1% | -2.7% |
| 1Y | -16.3% | -12.1% | 8.8% |
Return vs Industry: 0HNC underperformed the UK Biotechs industry which returned -12.1% over the past year.
Return vs Market: 0HNC underperformed the UK Market which returned 8.8% over the past year.
Price Volatility
| 0HNC volatility | |
|---|---|
| 0HNC Average Weekly Movement | 3.8% |
| Biotechs Industry Average Movement | 7.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.2% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0HNC has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0HNC's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 3,040 | Alexander Hardy | www.biomarin.com |
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company’s products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease; and ROCTAVIAN, an adeno associated virus vector for the treatment of severe hemophilia A. The company’s products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; BMN 349, an oral therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy.
BioMarin Pharmaceutical Inc. Fundamentals Summary
| 0HNC fundamental statistics | |
|---|---|
| Market cap | US$13.74b |
| Earnings (TTM) | US$426.86m |
| Revenue (TTM) | US$2.85b |
32.2x
P/E Ratio4.8x
P/S RatioIs 0HNC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0HNC income statement (TTM) | |
|---|---|
| Revenue | US$2.85b |
| Cost of Revenue | US$580.24m |
| Gross Profit | US$2.27b |
| Other Expenses | US$1.85b |
| Earnings | US$426.86m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.24 |
| Gross Margin | 79.67% |
| Net Profit Margin | 14.96% |
| Debt/Equity Ratio | 10.5% |
How did 0HNC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/11 07:57 |
| End of Day Share Price | 2025/03/10 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioMarin Pharmaceutical Inc. is covered by 53 analysts. 28 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Ishan Majumdar | Baptista Research |
| Huidong Wang | Barclays |